NCT06440603Not yet recruiting
EKLF Gene Expression in β-thalassemia
Erythroid Krüppel Like Factor (EKLF) Gene Expression in β-thalassemia Patients
Source: ClinicalTrials.gov · Last updated 4 Jun 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
1. Studying the effect of expression pattern of EKLF gene in β-thalassemic patients. 2. Detecting the correlation between the gene expression of EKLF and the clinical phenotype of β-thalassemic patients.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 19 May 2024
- Start date
- 1 Jul 2024
- Primary completion date
- 1 Jul 2026
- Lead sponsor
- Rofaida Hassan Ahmed
- Diseases
- Thalassaemia
- NCT number
- NCT06440603
What you commit to
- Study type: Observational
- Planned participants: 150
- From 1 Jul 2024 to the primary completion date, 1 Jul 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- patients with any other types of hemolytic anaemia
Who the study is looking for
- patients with β-thalassemia (major and intermedia).
- patients are of both sexes (male or female) at any age
Age in the registry: 5 years to 80 years · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.